PMID- 36226442
OWN - NLM
STAT- MEDLINE
DCOM- 20221221
LR  - 20230124
IS  - 1931-8405 (Electronic)
IS  - 0889-2229 (Linking)
VI  - 38
IP  - 12
DP  - 2022 Dec
TI  - Association of Human Leukocyte Antigen Alleles and Hypersensitivity of 
      Efavirenz/Nevirapine in HIV-Infected Chinese Patients.
PG  - 884-889
LID - 10.1089/AID.2022.0027 [doi]
AB  - To examine the association between human leukocyte antigen (HLA) and nevirapine 
      (NVP)- and efavirenz (EFV)-induced cutaneous adverse reactions in human 
      immunodeficiency virus (HIV) patients, we conducted a case-control study at our 
      center consisting of 96 patients. Patients were further assigned based on the 
      occurrence of cutaneous adverse events and the drugs involved. All patients were 
      subjected to next generation sequencing (NGS)-based screening with focus on HLA 
      phenotype, including the presence of HLA-B, HLA-C, and HLA-DRB1. Our data 
      indicated that the HLA-C*01:02:01 allele presence was observed in 47.4% (18/38) 
      of patients in the EFV-hypersensitivity group compared with 18.9% (7/30) in the 
      control group [odds ratio (OR) = 5.837; 95% confidence interval 
      (CI) = 1.727-19.722, p = .005]. In contrast, the occurrence of HLA-DRB1*08:03 was 
      found to be significantly lower in the EFV-hypersensitivity group (4/38, 10.5%) 
      compared with the corresponding control group (12/37, 32.4%) (OR = 0.148; 95% 
      CI = 0.035-0.625, p = .009). In addition, the HLA-DRB1*04:05:01 antigen was 
      expressed more frequently in the NVP-hypersensitivity group (23.8%, 5/21) 
      compared with the control group (10.8%, 4/37) (OR = 7; 95% CI = 1.265-38.793, 
      p = .026). Our data not only revealed a significant association between 
      HLA-C*01:02:01 and EFV-induced cutaneous adverse reactions but may also shed 
      light on defining the treatment for Chinese HIV patients.
FAU - Zhou, Xiao-Yan
AU  - Zhou XY
AD  - Department of Dermatology, First Affiliated Hospital of Kunming Medical 
      University, Kunming, China.
FAU - Li, Chong-Xi
AU  - Li CX
AD  - Department of HIV/AIDS, Third People's Hospital of Kunming City, Kunming, China.
FAU - Zhang, Jian-Bo
AU  - Zhang JB
AD  - Department of Dermatology, Second People's Hospital of Dali City, Dali, China.
FAU - Tan, Jun-Ting
AU  - Tan JT
AD  - Department of Dermatology, First Affiliated Hospital of Kunming Medical 
      University, Kunming, China.
FAU - -Yang, Xi
AU  - -Yang X
AD  - Department of Dermatology, First Affiliated Hospital of Kunming Medical 
      University, Kunming, China.
FAU - Albarmaqi, Rowida A
AU  - Albarmaqi RA
AD  - Department of Dermatology, First Affiliated Hospital of Kunming Medical 
      University, Kunming, China.
FAU - Li, Yu-Ye
AU  - Li YY
AUID- ORCID: 0000-0003-0676-985X
AD  - Department of Dermatology, First Affiliated Hospital of Kunming Medical 
      University, Kunming, China.
FAU - Kuang, Yi-Qun
AU  - Kuang YQ
AD  - NHC Key Laboratory of Drug Addiction Medicine, First Affiliated Hospital of 
      Kunming Medical University, Kunming Medical University, Kunming, China.
AD  - Scientific Research Laboratory Center, First Affiliated Hospital of Kunming 
      Medical University, Kunming, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221111
PL  - United States
TA  - AIDS Res Hum Retroviruses
JT  - AIDS research and human retroviruses
JID - 8709376
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Benzoxazines)
RN  - JE6H2O27P8 (efavirenz)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-C Antigens)
RN  - 0 (HLA-DRB1 Chains)
RN  - 99DK7FVK1H (Nevirapine)
SB  - IM
MH  - Humans
MH  - Alleles
MH  - *Anti-HIV Agents/adverse effects
MH  - Benzoxazines/adverse effects
MH  - Case-Control Studies
MH  - East Asian People
MH  - *Histocompatibility Antigens Class I/genetics
MH  - HIV/genetics
MH  - *HIV Infections/drug therapy
MH  - HLA Antigens
MH  - HLA-C Antigens/genetics
MH  - HLA-DRB1 Chains/genetics/therapeutic use
MH  - *Nevirapine/adverse effects
MH  - Drug Hypersensitivity/genetics
OTO - NOTNLM
OT  - cutaneous adverse drug reactions
OT  - efavirenz
OT  - human leukocyte antigen
OT  - nevirapine
EDAT- 2022/10/14 06:00
MHDA- 2022/12/16 06:00
CRDT- 2022/10/13 03:43
PHST- 2022/10/14 06:00 [pubmed]
PHST- 2022/12/16 06:00 [medline]
PHST- 2022/10/13 03:43 [entrez]
AID - 10.1089/AID.2022.0027 [doi]
PST - ppublish
SO  - AIDS Res Hum Retroviruses. 2022 Dec;38(12):884-889. doi: 10.1089/AID.2022.0027. 
      Epub 2022 Nov 11.